Seraxis
PrivateLast Round
Convertible Debt
Sep 24, 2026
Total Funding Raised
$59.02M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Seraxis is a biotechnology company that develops cell replacement therapies to provide a long-term cure for insulin-dependent diabetes by producing insulin to regulate glucose levels without requiring immune suppression.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Seraxis Comparables
Compare Seraxis with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| NewcelX Ltd. | 86% | |
| SymbioCellTech | 85% | |
| Encellin | 85% |
Seraxis Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Convertible Debt | Sep 24, 2026 | ||||
| Grant | May 13, 2025 | ||||
| Grant | Jun 14, 2024 | ||||
| Grant | May 14, 2024 | ||||
| Series C Extension | Sep 21, 2023 | ||||
Series C | Feb 9, 2021 |
Seraxis Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Frazier Healthcare Partners | Series C |
| ASAP Ventures | Series A |
| Frazier Life Sciences | Series C, Series C Extension |
| East West Capital Partners | Series A |
| JDRF | Series C, Series C Extension |
| GRI Fund | Series A |
| Maryland Stem Cell Research Fund | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 24, 2026
$10M raised in Seed Round.
- Aug 21, 2026
Monthly visitors increased 120% MoM.
Recent news
Latest coverage and updates
- receives_financingOct 5, 2026
Seraxis receives $11.2M financing for its merger and diabetes cell therapy in Canada and Maryland on Oct 5th '26
- attends_eventSep 25, 2026
Seraxis will participate in Noble Capital Markets' Emerging Growth Virtual Equity Conference on Oct 1st '26
- acquiresSep 11, 2026
Seraxis, Inc. was planning to acquire Sernova Corp. on Sep 7th '26.
Seraxis Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Seraxis's valuation, stock price, and market status.
Is Seraxis a public or private company?
Seraxis is a private company.
What is the current stock price of Seraxis?
Seraxis is a private company, so its shares have no public market price. Caplight tracks Seraxis's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Seraxis worth (valuation)?
Valuation information for Seraxis is not publicly available.
Can I buy Seraxis stock?
Seraxis shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Seraxis's last funding round?
Seraxis's most recent funding round was Convertible Debt on September 24, 2026.
Who are the main investors in Seraxis?
Key investors in Seraxis include East West Capital Partners, Maryland Stem Cell Research Fund.
Will Seraxis IPO soon?
No public IPO plans have been announced for Seraxis.
How can I track Seraxis secondary market activity?
Caplight tracks bids, offers, and trades in Seraxis's shares on secondary markets.